PA
CRNX icon

Parallel Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Parallel Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.2K Hold
913
– – ﹤0.01% 2372
2026
Q1 		$33.2K Sell
913
-312
-25% -$13.9K ﹤0.01% 2225
2025
Q4 		$57K Buy
1,225
+315
+35% +$14K ﹤0.01% 1778
2025
Q3 		$37.9K Sell
910
-87
-9% -$2.78K ﹤0.01% 1930
2025
Q2 		$28.7K Sell
997
-552
-36% -$17K ﹤0.01% 2021
2025
Q1 		$52K Buy
1,549
+50
+3% +$1.87K ﹤0.01% 1617
2024
Q4 		$76.6K Buy
1,499
+10
+0.7% +$559 ﹤0.01% 1403
2024
Q3 		$76.1K Hold
1,489
– – ﹤0.01% 1397
2024
Q2 		$66.7K Sell
1,489
-63
-4% -$2.91K ﹤0.01% 1374
2024
Q1 		$72.6K Buy
1,552
+1,113
+254% +$43.5K ﹤0.01% 1317
2023
Q4 		$15.6K Buy
+439
New +$13.5K ﹤0.01% 2089
2022
Q4 		– Sell
-6
Closed – – 3383
2022
Q3 		$0 Buy
+6
New +$122 ﹤0.01% 3194
2021
Q4 		– Sell
-6
Closed – – 3115
2021
Q3 		$0 Buy
+6
New +$126 ﹤0.01% 3096

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Parallel Advisors's CRNX Position: Q2 2026 in Review

Parallel Advisors held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 913 shares worth $34.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2372.

Parallel Advisors first reported a position in CRNX in Q3 2021 and has held it in 13 quarters since. The position peaked at $76.6K in Q4 2024. 185 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Parallel Advisors held 913 shares of Crinetics Pharmaceuticals worth $34.2K as of Q2 2026.
  • Parallel Advisors left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2372 holding.
  • Parallel Advisors first reported a position in Crinetics Pharmaceuticals in Q3 2021 and has held it in 13 quarters since.
  • Parallel Advisors's Crinetics Pharmaceuticals position peaked at $76.6K in Q4 2024.
  • 185 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.